Article
Macrophages target PVR/CD155 on colorectal cancer cells via REVERBα
2026-01-29
Abstract excerpt
<h4>Background&Aims</h4> Patients with microsatellite-instable (MSI) colorectal cancer (CRC) benefit from immune checkpoint therapy. For patients with microsatellite-stable (MSS) non-MSI tumors targeting alternative immune checkpoints, such as the Poliovirus receptor (PVR/CD155), may extend response to checkpoint inhibitors and thereby improve outcomes. The drugable transcription factor REVERBα ( NR1D1 ) is a m...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5f8757bf-6ed9-5318-a45d-b408c4de406c
- DOI
- 10.64898/2026.01.29.702476
